Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Testing efficacy or toxicity of a compound or composition
Reexamination Certificate
2006-12-12
2006-12-12
Romeo, David S (Department: 1647)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Testing efficacy or toxicity of a compound or composition
C514S012200
Reexamination Certificate
active
07147839
ABSTRACT:
The present invention is based on the discovery that a true tissue morphogen such as OP-1 provided systemically, alone in its mature dimeric form, or as part of a soluble complex, can induce new replacement tissue regeneration at a localized, permissive defect site distal to the site of administration. Specifically, systemically administered protein is sufficient to induce formation of new functional replacement tissue, sufficient to repair a local defect in a tissue, including skeletal or orthopedic tissues, liver, pancreas, lung, cardiac, renal, uterine, intestinal, gastrointestinal tissue. (As used herein, “orthopedic” or “skeletal” or “joint” or “chondrogenic” tissue is understood to encompass the skeletal and skeletal joint tissues: bone, cartilage, tendon, ligament, and synovial membrane tissues.) It further has been discovered that a single injection of morphogenic protein is sufficient to induce the desired biological effect, and that administration is not time-sensitive, provided mesenchymal progenitor cells are accessible to the defect site. That is, morphogenic protein can be provided to an individual having a local permissive defect site, shortly after creation of the defect, or at some significant time later, including, without limitation, after the initiation of fibrotic tissue formation. Thus, means now are available for enhancing restoration of tissue function and/or repair or regeneration of functional replacement tissue by systemically administering morphogenic protein, at times significantly after creation of the defect. The methods and formulations can be used to repair local defects without requiring surgical intervention; can enhance the rate and quality of new replacement tissue formation, particularly in compromised individuals with a reduced capacity to undergo spontaneous healing, and can be used to induce new tissue formation even after the initiation of fibrosis at the defect site. This discovery is disclosed in copending U.S. Patent Application filed on even date herewith, the disclosure of which is incorporated herein by reference.
REFERENCES:
patent: 4968590 (1990-11-01), Kuberasampath et al.
patent: 5011691 (1991-04-01), Oppermann et al.
patent: 5013649 (1991-05-01), Wang et al.
patent: 5169837 (1992-12-01), Lagarde et al.
patent: 5266683 (1993-11-01), Oppermann et al.
patent: 5585237 (1996-12-01), Oppermann et al.
patent: 5641743 (1997-06-01), Bohlen et al.
patent: 5652118 (1997-07-01), Ozkaynak et al.
patent: 5656593 (1997-08-01), Kuberasampath et al.
patent: 5849686 (1998-12-01), Kuberasampath et al.
patent: 5928940 (1999-07-01), Sampath et al.
patent: 5972884 (1999-10-01), Cohen et al.
patent: 6022853 (2000-02-01), Kuberasampath et al.
patent: 6077823 (2000-06-01), Kuberasampath et al.
patent: 6096706 (2000-08-01), Toback et al.
patent: 0714665 (1996-06-01), None
patent: 0723031 (1996-07-01), None
patent: 1 364 655 (2003-11-01), None
patent: WO 88/00205 (1988-01-01), None
patent: WO 90/11366 (1990-10-01), None
patent: WO 91/18098 (1991-11-01), None
patent: WO 92/00382 (1992-01-01), None
patent: WO 92/15323 (1992-09-01), None
patent: WO 93/00432 (1993-01-01), None
patent: WO 93/04692 (1993-03-01), None
patent: WO 93/05172 (1993-03-01), None
patent: WO 93/05751 (1993-04-01), None
patent: WO 93/16099 (1993-08-01), None
patent: WO 94/03200 (1994-02-01), None
patent: WO 94/03600 (1994-02-01), None
patent: WO 94/06399 (1994-03-01), None
patent: WO 94/06420 (1994-03-01), None
patent: WO 94/06449 (1994-03-01), None
patent: WO 94/10203 (1994-05-01), None
patent: WO 94/15949 (1994-07-01), None
patent: WO 94/15965 (1994-07-01), None
patent: WO 94/15966 (1994-07-01), None
patent: WO 94/21681 (1994-09-01), None
patent: WO 94/26892 (1994-11-01), None
patent: WO 94/26893 (1994-11-01), None
patent: WO 95/01801 (1995-01-01), None
patent: WO 95/05846 (1995-03-01), None
patent: WO 95/10539 (1995-04-01), None
patent: WO 95/10635 (1995-04-01), None
patent: WO 95/10802 (1995-04-01), None
patent: WO 95/14104 (1995-05-01), None
patent: WO 95/33830 (1995-12-01), None
patent: WO 96/01316 (1996-01-01), None
patent: WO 96/01845 (1996-01-01), None
patent: WO 96/14335 (1996-05-01), None
patent: WO 96/30038 (1996-10-01), None
patent: WO 96/36710 (1996-11-01), None
patent: WO 96/40297 (1996-12-01), None
patent: WO 97/32033 (1997-09-01), None
patent: WO 98/13509 (1998-04-01), None
Kumar et al., American J. Physiology, 1994, vol. 266, pp. F829-F832.
Benet, L, and Sheiner, L., in Goodman and Gilman's The Pharmacological Basis of Therapeutics, 1980, 6th Edition, pp. 1675-1737.
Basler, K. et al. Control of Cell Pattern in the Neural Tube: Regulation of Cell Differentiation by dorsalin-1, a Novel TGFβ Family Member.Cell73, 687-702 (May 21, 1993).
Bock, L. C. et al. Selection of single-stranded DNA molecules that bind and inhibit human thrombin.Nature355, 564-566 (Feb. 6, 1992).
Celeste, A. J. et al. Identification of transforming growth factor β family members present in bone-inductive protein purified from bovine bone.PNAS87, 9843-9847 (Dec. 1990).
Famulok, M. & Szostak, J. W. In Vitro Selection of Specific Ligan-binding Nucleic Acids.Angew. Chem. Int. Ed. Engl.31, 979-988 (1992).
Hogan, B. L. M. Bone Morphogenentic proteins: multifunctional regulators of vertebrate development.Genes&Development10, 1580-1594 (1996).
Jones, W. K. et al. Osteogenic Protein-1 (OP-1) Expression and Processing in Chinese Hamster Ovary Cells: Isolation of a Soluble Complex Containing the Mature and Pro-Domains of OP-1.Growth Factors11, 215-225 (1994).
Lee, Se-Jin. Expression of growth / differentiation factor 1 in the nervous system: Conservation of a bicistronic structure.PNAS88, 4250-4254 (May 1991).
Lyons, K. et al. Vgr-1, a mammalian gene related to Xenopus Vg-1, is a member of the transforming growth factor β gene superfamily.PNAS86, 4554-4558 (Jun. 1989).
Massague, J. The Transforming Growth Factor-β Family.Annu. Rev. Cell Biol.6, 597-641 (1990).
Mathiowitz, E. et al. Biologically erodable microspheres as potential oral drug delivery systems.Nature386, 410-414 (Mar. 27, 1997).
Ozkaynak, E. et al. Osteogenic Protein-2.J. Biol. Chem.267, 25220-25227 (1992).
Ozkaynak, E. et al. OP-1 cDNA encodes an osteogenic protein in the TGF-β family.EMBO J.9, 2085-2093 (1990).
Padgett, R. W. et al. A transcript from a Drosophila pattern gene predicts a protein homologous to the transforming growth factor-β family.Nature325, 81-84 (Jan. 1987).
Sampath, T.K. & Reddi, A. H. Homology of bone-inductive proteins from human, monkey, bovine, and rat extracellular matrix.PNAS80, 6591-6595 (Nov. 1983).
Sampath, T. K. et al. Bovine Osteogenic Protein is Composed of Dimers of OP-1 and BMP-2A, Two Members of the Transforming Growth Factor-β Superfamily.J. Biol. Chem.265, 13198-13205 (Aug. 5, 1990).
Storm, E. E. et al. Limb alterations in brachypodism mice due to mutations in a new member of the TGFβ-superfamily.Nature368, 639-643 (Apr. 14, 1994).
Takao, M. et al. Identification of Rat Bone Morphogenetic Protein-3b (BMP-3b), a New Member of BMP-3.Biochem. Biophys. Res. Comm.219, 656-662 (1996).
Tuerk, C.& Gold, L. Systematic Evolution of Ligands by Exponential Enrichment: RNA Ligands to Bacteriophage T4 DNA Polymerase.Science249, 505-510 (Aug. 3, 1990).
Vukicevic, S. et al. Localization of Osteogenic Protein-1 (Bone Morphogenetic Protein-7) During Human Embryonic Development: High Affinity Binding to Basement Membranes.Biochem. Biophys. Res. Comm.198, 693-700 (Jan. 28, 1994).
Weeks, D. L. & Melton, D. A. A Maternal mRNA Localized to the Vegetal Hemisphere in Xenopus Eggs Codes for a Growth Factor Related to TGF-β.Cell51, 861-867 (Dec. 4, 1987).
Wharton, K. A. et al. Drosophila 60A gene, another transforming growth factor β family member, is closely related to human bone morphogenetic proteins.PNAS88, 9214-9218 (Oct. 1991).
Wozney, J. M. et al. Novel Regulators of Bone Formation: Molecular Clones and Activities.Science242, 1528-1534 (Dec. 16, 1988).
Guo, X. et al., Osteogenic protein-1
Cohen Charles M.
Sampath Kuber T.
Curis, Inc.
Fish & Neave IP Group Ropes & Gray LLP
Gamett Daniel C
Romeo David S
LandOfFree
Methods for evaluating tissue morphogenesis and activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for evaluating tissue morphogenesis and activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for evaluating tissue morphogenesis and activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3677529